// App-Quantinova.ai

O09 : Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA

Researchers

Presenter

  • David Walker

Principal Investigators

  • Kevin Winthrop

  • Mark C Genovese

  • Bernard G Combe

  • Yoshiya Tanaka

  • Alan Kivitiz

  • Franziska Matzkies

  • Beatrix Bartok

  • Lie Ye

  • Ying Guo

  • Chantal Tasset

  • John S Sundy

  • Edward Keystone

  • Rene Westhovens

  • William Rigby

  • Gerd R Burmester

Medical Centers

  • Rheumatology, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, UNITED KINGDOM

  • Ophthalmology/LAD, Oregon Health & Science Univ, Portland, OR

  • CCSR Immunology Rheumatol, Stanford University, Palo Alto, CA

  • Rheumatology, CHU Montpellier, Montpellier University, Montpellier, FRANCE

  • Rheumatology, University of Occupational and Environmental Health, Kitakyushu, JAPAN

  • Rheumatology, Altoona Center for Clinical Research, Altoona, PA, USA

  • Epidemiology, Gilead Sciences, Foster City, CA

  • Biostatistics, Gilead Sciences, Inc, Foster City, CA

  • Rheumatology, Galapagos NV, Mechelen, BELGIUM

  • Rheumatology, Mount Sinai Hospital and University of Toronto, Toronto, ON, CANADA

  • Rheumatology, University Hospitals Leuven, Leuven, BELGIUM

  • Rheumatology, Dartmouth College USA, Lebanon, NH, USA

  • Rheumatology, Charité-University Medicine Berlin, Berlin, GERMANY

Locations

  • United Kingdom

  • United States

  • France

  • Japan

  • Belgium

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02889796

  • NCT02873936

  • NCT02886728

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved